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1 INTRODUCTION 
 
When it comes to investing and choosing the right place to allocate the free funds, a 
proper, detailed analysis of investment options has to be performed using the right tech-
niques, which in this case are ‘The Financial Ratio Analysis’ and ‘The Altman Z-score’- 
two of the various helpful tools in analyzing the company’s performance in order to 
make the right selection of stocks to be included in the investment portfolio. Therefore, 
by implementing the above-mentioned techniques in evaluating the performance of 
three major producers of orthopedic implants including Zimmer, Stryker, and Smith & 
Nephew, the author intends to identify the best performer in the group according to 
Profitability, Efficiency, Market Value, Liquidity and Leverage Ratios; and evaluate the 
probability of these companies going bankrupt within the next 20 months using Altman 
Z-score formula. The outcome of the research in a form of detailed, descriptive, ana-
lyzed calculation can be used by individual investors, as well as businesses, mutual 
funds and investment trusts intending to purchase stock from leading orthopedic implant 
manufacturers and deciding on the best alternative.  
 
Orthopedic implants are the healthcare products manufactured for curing people, among 
other things, from a disease called “rheumatoid arthritis”. According to Smolen et al. 
(2007) and Aletaha et al. (2007), “Rheumatoid arthritis is characterized by synovial in-
flammation and a high propensity to destroy iuxtaarticular bone and cartilage” which 
leads to an inevitable, costly surgery. This illness is mostly common in the bodies of 
humans after 50 years of age. Population aging, the outcome of the post-World War II 
baby boom period which happened in 1946-1964, is a serious issue which affects the 
whole world. The Healthcare sector, where the orthopedic implant manufacturers be-
long, is one of the fastest growing sectors nowadays. According to OECD Health Data 
(2011), “health spending continues to rise faster than economic growth in most OECD 
countries” and is expected to keep increasing in the coming years.  
 
Bringing the above-mentioned facts together, the author has identified an increasing, 
developing and expanding industry for a possibility of a profitable investment, and, 
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therefore, would like to expand the horizon and deepen the knowledge in the field of 
finance combining it with an insight from healthcare. 
 
1.1 Motivation for choice of research topic 
 
This sub-section helps to identify the motives behind the selection of topic and its field 
by providing some historical, background information of the author’s interests. 
As the topic suggests “Investing in the orthopedic implant field”, this is the thesis in the 
finance field with analysis of orthopedic implant segment of healthcare industry. The 
author, by using the Financial Ratio Analysis tool and the Altman Z-score model and 
applying them in the context of three leading manufacturers of orthopedic implants, 
intends to identify the best performer in the group and suggest the investment oppor-
tunity to an investor.  
The reason for choosing a finance topic comes from the author’s interest in the subject 
acquired by studying at Arcada University of Applied Sciences in Helsinki and Middle-
sex University in London. Moreover, the author has gained experience in performing 
Financial Ratio Analysis from several courses and feels experienced in doing it for this 
thesis. However, the author wants to deepen her knowledge of this and other tools by 
reading various articles, books and case studies on this topic. 
The interest in orthopedic implants comes from the course “Entrepreneurship” taken at 
Arcada University of Applied Sciences during author’s second year of studies. Together 
with two other students, the author came up with a business idea of producing orthope-
dic implants as the demand for these products is constantly increasing due, among other 
things, to the population ageing. However, by studying the major manufacturers of these 
products, the group realized that it might be too ambitious to set up this kind of business 
without the proper knowledge of the production process. Therefore, the group decided 
to focus on the current major problem associated with orthopedic implants which is hip 
wear. Hip implants tend to wear very fast and need replacement. The group worked 
whole summer 2010 at Arcada’s laboratory to try to solve the problem. Through this 
practical training, several professional contacts were established. The group has visited 
the leading manufacturers’ premises in Vantaa and scientists doing research in the field. 
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The author has gained a lot of information on orthopedic implants during the Entrepre-
neurship module and practical training and would like to expand her knowledge of the 
field and follow the current trend and changes. Moreover, the author would like to work 
for one of the major players in orthopedic implant field and feels this research can help 
gain a deeper knowledge of the products and industry and become a prosperous candi-
date for working in the area. 
By combining these two fields together, the author intends to identify the strongest per-
former in the field to invest into. The interest for the investment evaluation also comes 
from the author’s interest in investing into shares of this business. However, the prob-
lem arises from the lack of knowledge on financial performance of these companies. By 
applying the selected tools, the author’s goal is to identify the best stock to buy based on 
the outcome of the calculation. 
 
1.2 Research aim 
 
By looking at graphs of stock performance of Zimmer, Stryker and Smith&Nephew 
available at New York Stock Exchange’s and London Stock Exchange’s websites, it is 
clearly evident that the stock of orthopedic implant manufacturers keeps increasing in 
price which leads to an increase in capital gains for the investors. However, the author 
wants to identify the leading company in terms of profitability for an investor. There-
fore, the aim of this research is to compare ratios performed for each company with its 
peers and rank the companies from the investor’s point of view.  
 
1.3 Research questions 
 
“What is the best performer among Zimmer, Stryker and Smith&Nephew based 
on applied Financial Ratio Analysis?” 
 
Based on researching the theories on Financial Ratio Analysis and the annual reports 
and information available on orthopedic implant industry the author intends to perform 
the calculations for the three above-mentioned corporations and identify the strongest, 
fastest growing and most profitable player in the field. 
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“What is the probability of Zimmer, Stryker or Smith&Nephew going bankrupt 
within the next 20 months based on Altman’s Z-score model?” 
 
By applying Altman Z-score model for the three above-mentioned companies the author 
intends to evaluate the probability of them going bankrupt within the next 20 months. 
Therefore, the answer to this question gives investor an insight into the future. 
 
“What is the best investment among Zimmer, Stryker and Smith&Nephew based 
on the author’s judgment?” 
 
Orthopedic implant industry represents a very profitable niche for the investor’s deci-
sion choice. By studying the produced results, the author intends to select the major 
criteria for judgment of the companies and identify the best performer based on the 
analysis. 
 
1.4 Theoretical framework 
 
Gardiner et al. (1995) states that ratio analysis continues to represent one of the finan-
cial world’s most powerful and versatile tools. As an addition to that, Bodie, Kane and 
Marcus (2009) state that in order to evaluate the performance of a given firm, there 
needs to be a benchmark to which to compare its ratios and offer the comparison of the 
firm with those from the same industry as an example. Keown, Martin and Petty (2010) 
add that the examination of the historical performance for the purpose of comparison of 
a firm’s current and past performances gives the analyst a deeper and broader under-
standing of a particular company’s operations. On top of that, Frank et al. (1950) points 
out that ratios should not only be compared with the past figures and industry averages, 
but also are best understood when reviewed as a group rather than individually because 
the cause of bad outcome of one calculation might come from a performance of another 
ratio. Hitchings (1999) adds that the analyst should take into account the industry dy-
namics; political and economic situations happening in the world and the company-
specific issues. Eakins (2002) argues that financial ratio analysis is not useful to all 
firms and further explains that corporations engaged in various businesses could be hard 
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to analyze because the annual figures for all divisions are usually brought in one finan-
cial statement and could be difficult to distinguish.  
 
Hitchings (1999) and Mautz et al. (2006) propose a five-year timeframe as the optimal 
timeframe for computing the Financial Ratio Analysis. Moreover, Hitchings (1999) 
adds that Financial Ratio Analysis does not provide any wrong or right answers and it 
only points out the areas to be investigated. Mautz et al. ( 2006) agrees with that and 
adds that Financial Ratio Analysis can be a powerful tool to pinpoint the areas to be 
improved and is the first step towards implementing effective policy. Therefore, by ap-
plying Financial Ratio Analysis in the context of this thesis the author intends to identi-
fy the weak and strong sides of each company. 
 
Altman (1968) questions the ability of the ratios to predict the corporate bankruptcy 
and, therefore, offers a tool that can be used in order to measure the probability of a 
corporate bankruptcy within 20 months called ‘Altman Z-score’. Altman (1968) uses 
Multiple Discriminant Analysis defined as “a statistical technique used to classify an 
observation into one of several a priori groupings dependent upon the observation’s 
individual characteristics” and applies it to construct the Z score. Out of 22 selected 
ratios, Altman (1968) further identifies five ratios that are doing the best job in predict-
ing the corporate bankruptcy and assigns each a weight in the formula. 
 
Even though, there has been done a lot of research on the Financial Ratio Analysis, it 
either has not been publicly available or applied in the context of comparing the perfor-
mance of orthopedic industry major players. For the purpose of this study, the compa-
nies’ performances are compared with the past, with the competitors from the same in-
dustry and, also, evaluated as one whole group for each firm. The figures used in the 
calculations are taken from annual reports available on the websites of the studied com-
panies. Therefore, the author intends to deepen the knowledge of finance by analyzing 
companies’ annual reports and performing ratio calculations from figures available in 
the reports 2006-2010
1
.  
 
                                                          
1
 2006-2010 is a five-year timeframe used by the author of this particular case 
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1.5 Demarcation 
 
First of all, using two techniques for evaluating companies and making an investment 
decision is very limiting in itself. Such theories as CAPM (Capital Asset Pricing Mod-
el), WACC (Weighted Average Cost of Capital), Portfolio diversification theory, Du 
Pont Ratio Analysis and various others are used by investors when evaluating the in-
vestment decision. Investors differ in their choices of tools and techniques applied in 
their research. Therefore, by being bounded by time and page limit it is not possible to 
perform and use all the theories in one thesis. Therefore, the author decided to focus on 
Financial Ratio Analysis and Altman Z-score in order to gain a deeper, thorough 
knowledge of the tools and their usability.  
 
Moreover, the calculation is based on analyzing three major producers of orthopedic 
implants in UK and USA. However, there are other existing manufacturers in these 
countries, as well as in developing countries and the rest of the world. The selection of 
the companies is based on the size and global presence. All selected candidates are huge 
market cap stock listed companies leading their industry.  
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2 LITERATURE REVIEW 
 
2.1 Investment defined 
 
Bodie et.al. (2009) defines investment as ”the current commitment of money or other 
resources in the expectation of reaping future benefits”. Investment is the process of 
employing the money in order to earn a profit in the future. There are various types of 
investment and Millard (1998) provides the list of most popular forms of it including 
Building Society Deposits, Clearing Bank Deposits, National Savings Certificates, Na-
tional Savings Index-linked, National Savings Investment Account, TESSAS ( Tax Ex-
empt Special Savings Accounts), ISAS (Individual Savings Accounts), Collectors’ 
Items and The Stock Market.  
 
The focus of this study is on investment into the shares of blue chip companies traded 
on New York Stock Exchange and London Stock Exchange as an opportunity for a 
portfolio diversification. Stock Exchanges deal with two types of securities: fixed-
interest stocks and ordinary shares. Fixed-interest stocks offer a fixed rate of interest to 
its holder and are issued as “gilts” by the government or “preference shares” by the 
companies. Meanwhile, ordinary shares are issued by the companies and provide the 
holder with return in two forms: capital gain and dividend payments. Dividend pay-
ments do vary with years depending on success and profitability of the business. It 
might happen so that dividends are retained for future expansion and not paid at all. 
Capital gain is the difference between the purchase price and selling price earned by an 
investor. Share price fluctuates every day depending on the economy, competition, in-
novations, business success and various other factors. Therefore, it is important for an 
investor to follow the price movement of particularly held shares in order to maximize 
the gain and decrease the probability of loss.  
 
When investing into the Stock Market the investor has to thoroughly understand several 
factors which play an important role for the procedure. The first factor is Return on In-
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vestment which is the income obtained from dividend payment plus capital appreciation 
of the shares. The formula for ROI is as follows: 
Return on Investment =  
                                       
                  
 
This formula is further applied for each studied company and compared.  
 
The second factor is Risk involved. As one of the basic principles of finance states 
“Risk requires reward”. The higher the risk associated with the investment, the higher 
the return will be. People demand higher return for taking on additional risk in order to 
secure their money.  
 
The third factor is the efficient market hypothesis which states that market prices are 
generally right. Keown et al. (2011) states that efficient market “is the one where the 
prices of the assets traded in that market fully reflect all available information at any 
instant of time”. The information is available on stock exchanges where the shares are 
traded, as well as in the companies’ annual reports easily downloadable from the official 
websites of the companies.  
 
The fourth factor is that the main goal of publicly listed companies is to maximize the 
shareholder wealth. Shareholders are the legal owners of the company and the board of 
directors which is elected by shareholders’ voting exists to achieve this goal. Maximiza-
tion of shareholder wealth means maximizing the market value of the existing stock.  
 
The fifth factor is time. The investor needs to define the timeframe of the investment 
and search for the shares accordingly. Some investors tend to look for short-term gains, 
while others invest in the long run to be able to afford paying for the kid’s education or 
buying a house within couple of decades.  
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As Millard (1998) notes, the ideal investment would have a high return, high liquidity, 
low risk and take minimal time to manage. However, this is not possible to obtain by 
investing into one type of security, therefore the investor has to accept a degree of trade-
off and therefore diversify the portfolio of securities. Investment into shares of orthope-
dic implant blue chip companies is offered by author as an alternative for a portfolio 
diversification. 
 
2.2 Profitability of investment into ordinary shares. 
 
 
Ordinary share, or, common stock is defined by Bodie (2009) as “a certificate that indi-
cates ownership in a corporation”. Shareholders are the true owners of the firm and the 
company exists in order to maximize their wealth. Common stock exists as long as the 
company operates and has no maturity date. Profit from holding shares comes from div-
idends and capital gains.  
 
Dividend is a share of the company’s net income paid to the holders of the stock. The 
companies can either retain the earnings for keeping the business growth or pay certain 
share of earnings to its shareholders. High-growth companies rarely offer dividend 
payments and keep the earnings for future expansion (for example, Zimmer).  
 
Capital gain is the difference between the purchase price and selling price of the share. 
Capital gain is also called as “investment income”. It is not always the case that inves-
tors gain income from their investment. It might be a capital loss when investors lose 
money on their investment.  
 
In order for the investment into shares of orthopedic implant companies to be consid-
ered profitable, it needs to have higher dividend payments and higher capital gains. The 
 15 
 
author evaluates profitability of investment into Zimmer, Stryker and Smith&Nephew 
for the period 2006-2010. 
 
2.3 Financial Ratio Analysis 
 
 
When it comes to investing, financial ratio analysis can become one of the helpful tools 
in analyzing the company’s performance in order to make the right selection of stocks to 
be included in the investment portfolio. Financial ratio analysis is based on analyzing 
and evaluating the company’s financial statements including income statement, balance 
sheet and cash flow statement and producing a certain set of calculations based on the 
figures provided in the annual reports. This technique is widely used among various 
financial professionals worldwide. Investors, among others, use it when comparing dif-
ferent companies’ performances and selecting the ones to purchase shares from. 
 
Ratio analysis in itself is meaningless unless used within two contexts: vertical and hor-
izontal analysis (Hitchings, 1999). The purpose of horizontal analysis is to compare the 
company’s performance over a number of years. The outcome of the comparison is to 
identify trends which will give insight into the future performance. Ratio analysis does 
not give any forecasts or predictions for the analysts but allows to identify the areas 
which require further investigation. On the other hand, the purpose of vertical analysis 
is to compare firms in the same industry, determine the difference from the norm and 
investigate the outcome.   Hitchings (1999) and Mautz et al. (2006) suggest a five-year 
timeframe as an optimal solution for both vertical and horizontal analyses. Moreover, 
when performing an analysis, it is important to pay attention to economic and political 
situations; industry dynamics and company-specific issues as insights from that areas 
will help understand and interpret the ratios.  
 
Various institutions and professionals have different subdivision categories for the rati-
os, however, according to Bodie (2009); the ratios are broken down into five categories: 
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Figure 1. Financial Ratio Analysis  
 
2.3.1 Liquidity 
 
According to the definition, liquidity is the firm’s ability to meet its immediate and 
short-term obligations with cash when needed. The liquidity-riskiness relationship 
shows that the less liquid the firm is, the more risky its securities are considered; while 
the more liquid the company is, the more financially strong it is. Therefore, investors 
look for more liquid firms in case to avoid the possibilities of future bankruptcy. 
 
According to Jenny Kähtävä (see Appendix), Quick ratio is one of the most important 
liquidity ratios.  
Table 1. Liquidity  
 # Ratio Formula 
 
1 
 
Quick ratio 
 
                                              
                   
 
 
Profitability 
ratios 
Financial 
Ratio Analysis 
Leverage 
ratios 
Liquidity 
ratios 
Market 
ratios 
Efficiency 
ratios 
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Quick ratio measures the ability of using company’s cash, marketable securities and 
accounts receivable to reduce its current liabilities.  
 
2.3.2 Profitability 
 
Profitability ratios include ROA (return on assets), ROE (return on equity), Gross Profit 
Margin and Profit Margin. These four ratios measure the ability of the company to gen-
erate earnings. In order to be financially attractive for investors, firms need to produce 
positive profits from their assets, equity and sales. The amount of dividend payment and 
its increase has direct dependence on profitability. According to Grullon et al. (2003), 
“one of the most important predictions of the dividend-signaling hypothesis is that divi-
dend changes are positively correlated with future changes in profitability and earn-
ings”. Companies with increasing earnings are of a great attractiveness to shareholders 
as dividend payments and capital gains are positively dependent on the increase in prof-
its. 
Table 2. Profitability  
# Ratio Formula 
 
1 
 
Return on assets 
 
    
            
 
 
 
2 
 
Return on equity 
 
          
                    
 
 
 
3 
 
Gross Profit Margin 
 
                        
     
 
 
 
4 
 
Profit Margin 
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Return on assets ratio measures the rate of return that the firm’s assets produce. The 
outcome of the calculation is affected by the industry the firm belongs to. The higher 
the ROA, the better. 
 
Return on equity ratio is the measure of how well the shareholder’s money is handled 
and which percentage of the total income they contribute to. ROE figure is higher when 
the company uses more debt financing assuming that the company produces higher re-
turn on assets than the interest rate is. However, the use of debt finance results in higher 
risk for investors.   
 
Gross Profit Margin, also known as gross margin and gross margin rate, shows the 
difference between selling price and cost. The percentage represents how much of each 
dollar of sales the company retains for paying off its selling, general and administrative 
expenses.  
 
Profit Margin shows the percentage of earnings from the total Sales figure. The higher 
the margin, the better control over costs the company has.  
 
2.3.3 Leverage 
 
Keown.A (2008) states that “financial leverage means financing a portion of the firm’s 
assets with securities bearing a fixed (limited) rate of return in hopes of increasing the 
ultimate return to the common stockholders”. Firms use debt financing in order to in-
crease its profitability and increase the stocks’ value. Debt ratio is used for assessing the 
proportion of debt finance the firm uses for its operations. The use of leverage finance 
increases the financial risk of the company with an impact of an increased risk for in-
vestors. 
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Table 3. Leverage  
# Ratio Formula 
 
1 
 
Debt ratio 
 
                 
            
 
 
 
Debt ratio measures the percentage of debt financing used in a firm’s capital structure. 
Ratio greater than 0.5 indicates that the company uses more debt than equity for financ-
ing its operations which results in an increase of financial risk for the future of the busi-
ness, as well as for the investors. Ratio less than 0.5 indicates that the company uses 
more equity financing for its operations and the risk of firm not being able to pay back 
its obligations is reduced. Debt ratio of one company is usually compared with the firms 
in the same industry or competitors and adds to the components affecting investor’s 
decision. 
 
2.3.4 Efficiency  
 
Efficiency, according to the definition, is “an accomplishment of or ability to accom-
plish a job with a minimum expenditure of time and effort”; it is an ability of a company 
to utilize its resources with the minimum expenditure and maximum productivity in 
order to stay within the competition and win the market share of a certain territory. Effi-
ciency ratios examine the internal management of company’s resources and liabilities. 
Improvement in the efficiency of the company leads to an improvement of profitability 
which further increases the market ratios measures. Therefore, there is an interconnec-
tion between all the ratios in the financial ratio analysis.  
 
Total Asset Turnover, Fixed Asset Turnover, Inventory Turnover are the ratios used to 
measure the level of efficiency of a firm.  
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Table 4. Efficiency  
# Ratio Formula 
 
1 
 
Total Asset Turnover 
 
         
            
 
 
 
2 
 
Fixed Asset Turnover 
 
         
                    
 
 
 
3 
 
Inventory Turnover 
 
                  
         
 
 
 
Total Asset Turnover ratio measures the level of utilization of assets. This ratio 
measures how many dollars of sales are produced from one dollar of assets. The higher 
the outcome of the calculation, the better the company uses its assets for generating 
sales. Companies tend to outperform its competitors by efficiently utilizing their assets. 
 
Fixed Asset Turnover ratio is similar to Total Asset Turnover ratio, however in this 
case average fixed assets are taken instead of total assets. Fixed assets are also known as 
Property, Plant and Equipment and are neither liquid nor easily convertible into cash. 
The higher the figure, the better the utilization of the fixed assets is.  
 
Inventory Turnover ratio measures how many times the turnover is rolled over during 
the year and how fast the inventories are transformed into sales. High figure indicates 
that inventories kept in the warehouse are sold quickly and not kept for long times. 
Lower calculation outcome implies increase in stock holding costs and difficulties in 
selling stock. 
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2.3.5 Market Value 
 
 
Market ratios are the most important indicators for this thesis as they are intended to 
measure whether the company is increasing shareholder value and creating a good re-
turn on invested capital. These measures are the ones that apply to investors’ major in-
terest when browsing through financial ratio figures. Market ratios reflect the current 
state of the share market price and the amounts of dividend payments. There is a direct 
relationship between market ratios and profitability, leverage, liquidity and efficiency 
ratios: if the company is increasing its sales, liquid, efficient and is able to pay its obli-
gations, then it is seen as an attractive opportunity for investment. Market value analysis 
also helps to determine whether stock is underpriced or overpriced. The components of 
this work’s market value ratios include Earnings per share; Price-to-earnings ratio; 
Earnings yield.  
 
Table 5. Market value  
# Ratio Formula 
 
1 
 
EPS 
 
            
                
 
 
 
2 
 
P/E Ratio 
 
                      
                  
 
 
 
3 
 
Earnings yield 
 
                  
               
 
 
 
EPS which stands for Earnings per share is a percentage of company’s earnings as-
signed to each outstanding share being issued.  The formula is usually calculated twice: 
first time for basic and second time for diluted shares. In case there are diluted shares, 
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the outcome of the calculation is lower earnings per share figure as the net earnings are 
divided by the higher number of shares. Some companies also have adjusted earnings 
per share which is calculated using the adjusted net earnings. 
 
Price-to-earnings ratio indicates the willingness of the market to pay for the compa-
ny’s earnings. Higher figure shows that the market believes in the future of the compa-
ny’s prospects and the price is, therefore, high for the shares. However, on the other 
hand, if the figure is low then investors do not have hopes for the prosperous future of 
the firm’s operations and the price for the share is low. P/E ratio shows how much 
shareholders are ready to pay for one dollar of earnings. 
 
Earnings yield ratio is the inverse of P/E ratio and measures the return on every dollar 
invested in the company.  
 
2.3.6 Limitations of Financial Ratio Analysis 
 
Financial ratio analysis is a useful tool for analyzing company’s performance; however, 
it has certain pitfalls and drawbacks about which analysts need to be aware before per-
forming the calculations in order to avoid false misinterpretations of results. The prob-
lems associated with the analysis include: 
 
 According to Generally Accepted Accounting Principles (GAAP), there are var-
ious ways of representing items in financial statements. Therefore, it might have 
an impact on ratio calculations. As an example, Bodie (2009) points out differ-
ences in inventory valuation, depreciation, inflation and interest expense. 
 
 There are two ways of valuing inventories: LIFO (last-in first-out) and FIFO 
(first-in first-out). The LIFO principle estimates the inventory at the current cost 
of production, while the FIFO system estimates the inventory at original cost. 
The result of this is that the FIFO firm has a higher profit and a higher balance 
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sheet value than the LIFO firm. Therefore, this might create distortion in calcu-
lations and interpretations of results. 
 
Depreciation is another confusion creating problem as firms use different depre-
ciation methods including accelerated and straight-line methods. Moreover, 
firms differ in estimating the lifespan of depreciable assets. 
 
Inflation has an impact on calculation of leverage ratios. What is considered as 
interest expense might be a part of principal repayment. 
 
 Determination of the firm belonging to a certain industry might become a com-
plicated task in case the company is engaged in various types of businesses.  
 
 Financial Ratio analysis is a quantitative analytical tool providing the analyst 
with numbers only. Therefore, it does not measure the quality of the company’s 
operations or customer service which plays an important role in financial per-
formance. 
 
 Financial Ratio Analysis is intended for measuring the past performance of the 
firm and does not provide future forecasts. However, financial analysts try to 
construct the future predictions based on the past performance. 
 
 Ratios do not provide a good base for judgment unless compared with the indus-
try norms, competitors and reviewed as interdependent variables. 
 
 As with risk perception and net present value calculation, where there is no uni-
versal correct figure, same is applied to Financial Ratio Analysis. There is no 
right or wrong ratio. Analysts differ in their perceptions and judgment, therefore 
the interpretations of financial ratio analysis might differ among people. 
 
 Ratio Analysis calculations are based on the numbers provided in the statements 
of operations assuming the data is correct. In case the information is wrong, the 
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result of analysis is misleading too. Therefore, there is a problem of window 
dressing when companies try to show the financial position in a better way.  
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2.4 Altman Z-score 
 
Financial Ratio Analysis is used for evaluating the company’s past performance and 
does not give an insight into the future. However, it is not enough for an investor to look 
at historical figures only. The future of the company needs to be analyzed also. There-
fore, for this purpose Altman Z-score is calculated for each of three companies in order 
to evaluate the companies’ probability of bankruptcy within the next 20 months (Alt-
man, 1968). Z-score formula measures the corporate financial health. 
 
Edward I. Altman is a Finance Professor at the University of New York. He is famous 
for establishing Z-score model for predicting corporate bankruptcy in 1968. The model 
helps investors to reduce risk and make investment safer. The variables used for calcu-
lating are derived from the company’s Balance Sheet, Profit & Loss and Cash Flow 
Statements. The formula for Z-score is as follows: 
 
Z= 1.2*X1 + 1.4*X2 + 3.3*X3 + 0.6*X4 + 1.0*X5, 
 
Where: X1= Working Capital/Total Assets 
 X2= Retained Earnings/Total Assets 
 X3= EBITDA/Total Assets 
 X4= Market Value of Equity/Total Liabilities 
 X5= Net Sales/Total Assets 
 
X1, Working Capital/Total Assets 
This ratio measures the liquidity of the firm by comparing its working capital to total 
assets. Altman (2000) states that among the liquidity ratios including current and quick 
ratios, this ratio has proved to be the most valuable.   
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X2, Retained Earnings/Total Assets 
This ratio measures the leverage of the firm and what the percentage of retained earn-
ings used for financing the total assets is. Altman (2000) calls this ratio ‘new ratio’. 
Moreover, he states that young companies tend to have lower retained earnings as they 
have not been able to build a cumulative retained earnings figure yet, which leads to a 
lower X2 figure and higher risk of bankruptcy, which actually reflects the real world 
situation. Dun&Brandstreet (2004) state that 50% of firms that failed in 1993 did it in 
the first five years of their existence.   
 
X3, EBITDA/Total Assets 
This ratio measures the firm’s efficiency in utilizing its assets. Altman (2000) states that 
“the firm’s ultimate existence is based on the earning power of its assets” and this ratio 
is intended to measure the earning power of the total assets. The higher the earning 
power of the company, the lower the risk of bankruptcy is. 
 
X4, Market Value of Equity/Total Liabilities 
This is the ratio for measuring the firm’s solvency. It assesses whether the company is 
able to pay for its liabilities in case the creditors suddenly reclaim the loans.  
 
X5, Net Sales/Total Assets 
The total asset turnover ratio measures the effect of utilization of the firm’s assets on 
generating sales. The higher this ratio, the better is the company in generating more 
sales by efficiently using its assets. 
 
Charley Kyd (2008) classifies Z-score formula into 3 versions:  
1. Z-score for private manufacturing companies,  
2. Z-score for public manufacturing companies and, 
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3.  Z-score for private non-manufacturing companies.  
 
The difference between the formulas is in coefficients attributed to each variable. More-
over, Z-scores for private companies and for general use do not include X4 variable 
which includes the Market Value of equity, but instead have a different variable replac-
ing the missing one.  Z-score for private non-manufacturing companies does not include 
X5 variable as firms from different industries have different levels of asset turnover and 
the ratio result might be misleading.  
 
Altman (2000) clarifies that variables should be included in the formula as absolute per-
centage values (0.2 instead of 20%). 
 
2.4.1 Interpretation 
 
The figure produced after plugging in the variables and multiplying them with the at-
tributed variables needs to be analyzed by comparing it with the interpretations, which 
are as follows: 
 
 Z ˂ 1.8 = “Distress zone”, the probability of bankruptcy is very high, 
1.8 ˂ Z ˂ 2.7 = “Grey zone”, the probability of company going bankrupt within 20 
months is possible, 
2.7 ˂ Z ˂ 2.99 = “On Alert”, the investor should be very cautious when investing into 
these companies, 
Z ˃ 2.99 = “Safe zone”, the probability of company going bankrupt is low. 
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2.5 Population Projection 
 
Population ageing trend has an impact on the increasing demand for healthcare products 
and pharmaceuticals around the globe. Older people tend to require more care and have 
higher rate of chronic illnesses development than the younger part of the population. 
According to a UN report (2009), people aged 55 or above represent 22% of the popula-
tion in the developed and 9% in the developing countries. These figures will be con-
stantly increasing in the future and will reach 33% and 20% respectively by 2050. 
 
Research on the target population (Biomet, 2011) has shown that males and females in 
the age range 55-75 years represent the customers of orthopedic implants. Kotler et al. 
(2010) defines target market as a “set of buyers who share common needs or character-
istics that the company decides to serve”. Therefore, the age group of 55-75 which be-
longs to an ageing population represents the main customers of orthopedic implant 
manufacturers.  
 
It is a vital part of this research to look at the projections of US and UK population be-
longing to the identified age range as Zimmer and Stryker are American-based compa-
nies with biggest share of sales in the United States and Smith&Nephew is a UK-based 
company with the biggest share of sales represented by a British market. 
Data derived from the U.S. Census Bureau Projections shows that the population will be 
ageing. Amount of People in the age group 55-74 will increase by 53% by 2051.  
  
Figure 2. US projected population aged 55-74. 2010-2050 
57 738 000 
88 224 000 
0 40 000 000 80 000 000
2010
2050
US Projected Population 
Age 55-74 (mil) 
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Table 6. Population change US (%) 2010-2050  
(million) 2010 2050 % increase 
Total Population 310233 439010 41,5% 
55-74 years old 57738 88224 53 % 
 
Data derived from Office for National Statistics of UK also shows that the population will be 
ageing. The increase in the age range 55-75 is expected to be 33% by 2051
2
.  
 
 
Figure 3. UK projected population aged 55-75. 2010-2051  
Table 7. Population change UK (%) 2010-2051  
(million) 2010 2051 % increase 
Total Population 61,38 77,07 25,5% 
55-75 years old 12,43 16,54 33% 
 
Population projection is a good base for prediction of the demand for the products of the stud-
ied companies. With the ageing of population, there will be an increase in 55-75 age range 
category that represents the target market of orthopedic implant manufacturers. Therefore, the 
demand for the healthcare products including orthopedic implants, the field where Zimmer, 
Stryker, Smith&Nephew operate will increase. In order to meet the increased demand, the 
increased supply is expected to occur. Therefore, the companies will have to produce more 
                                                          
2
 The data from Office for National Statistics UK is available for years 2010 and 2051. Therefore, there is a 1 
year difference between US statistics of 2050 and UK statistics of 2051 
12,43 
16,54 
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orthopedic implants in order to meet the demand. This leads to increase in Sales and Profits 
for the companies. 
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3 ORTHOPEDIC IMPLANT INDUSTRY ANALYSIS 
 
3.1 Introduction 
 
The orthopedic implant industry analysis section includes several topics: Industry Average; 
Descriptions of Stryker, Zimmer, and Smith&Nephew; Financial Ratio Analysis Results 
shown with the help of graphs; Altman Z-score results; Return on Investment and Internal 
Rate of Return calculations. 
 
Industry Average is used as a benchmark for comparison in the financial ratio analysis sec-
tion. The author performed financial ratio analysis for 10 top orthopedic implant manufactur-
ers including Stryker, Zimmer, Smith&Nephew, Kensey Nash, Johnson&Johnson, Wright, 
Exactech, Synthes, Integra Lifesciences, and Medtronic and further calculated the mean for 
each ratio for each year.  
 
Descriptions of the companies include the brief history, operations and business, net sales and 
growth, global presence and information about the listing on stock exchanges. The infor-
mation is taken mainly from the companies’ websites and also from various other sources 
including magazines and articles. 
 
Financial Ratio Analysis includes 12 ratios shown separately. Each ratio description includes 
the graph with the three companies and the industry average and clarification of results.  
 
Altman Z-score is calculated for each company separately and results are shown in the table. 
The results are further interpreted by comparing to the Altman’s rule of interpretation. 
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Return on shares includes return on investment and internal rate of return calculations which 
measure the profitability and yield of particular investments. 
 
The figures for the calculations are taken from the companies’ annual reports available online. 
Balance sheet, Profit & Loss and Cash Flow Statements are the three key financial sheets used 
for this research. 
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3.2 Industry Average 
 
As Bodie et al. (2009) states, financial ratio analysis needs to be compared to a benchmark 
being an industry average. Even though information on industry benchmark exists, it is not 
publicly available online. It can be purchased for a certain amount of money. However, the 
author decided to create an industry average herself. The author performed Financial Ratio 
Analysis for 10 top orthopedic implant industry companies including Stryker, Zimmer, 
Smith&Nephew, Kensey Nash, Johnson&Johnson, Wright, Exactech, Synthes, Integra 
Lifesciences, and Medtronic (“20 of the most profitable Orthopedic and Spine device Compa-
nies”, Miller, L., 2011) and further calculated the mean for each ratio. The industry bench-
mark is used further in the work to analyze the performance of the three studied companies. 
The industry benchmark can be found below. 
Table 8. Industry Average  
 2006 2007 2008 2009 2010 
Quick ratio 1,94 2,93 2,24 2,80 2,89 
ROA 14 % 12% 13% 13% 14% 
ROE 17 % 14 % 15 % 14 % 15 % 
Gross Profit Margin 72 % 72 % 71 % 71 % 72 % 
Debt Ratio 32 % 36 % 39 % 36 % 37 % 
Gross Profit Margin 16 % 13 % 13 % 14 % 15 % 
Profit Margin 16 % 13 % 13 % 14 % 15 % 
Total Asset Turnover 0,71 0,69 0,70 0,68 0,65 
Fixed Asset Turnover 5,05 5,05 5,1 4,9 4,9 
Inventory turnover 1,65 1,49 1,96 1,80 1,82 
EPS basic 1,91 1,76 1,98 2,15 2,46 
P/E ratio 28,41 33,13 19,99 16,54 14,87 
Earnings yield 4,2 % 3 % 4,7 % 5 % 5,7 % 
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3.3 Stryker 
 
Stryker, among Zimmer and Smith&Nephew, is one of the leading orthopedic implant manu-
facturing companies in the world. The history of the corporation dates back to 1941 when Dr. 
Homer Stryker established an Orthopedic Frame Company being the only shareholder of 
5,000 shares worth 20,000$.  
 
Stryker operates in 89 countries worldwide. America is the main market of the company, 
while the rest of the world represents 35% of the sales share. Stryker is headquartered in 
Michigan and most of its manufacturing facilities are located in the United States. However, 
Stryker operates plants in Germany, Switzerland, France, Ireland, China, Georgia, and Puerto 
Rico. 
 
The two key business areas are orthopedic implants (59%) including hip implants, knee im-
plants, craniomaxillofacial implant systems, spinal implants, trauma implants, bone cement, 
and, MedSurg equipment (41%) including surgical equipment and navigation systems, endo-
scopic and communication systems, medical device products and emergency room equipment. 
 
Stryker was number 323 largest U.S. company in 2011 (Fortune 500, 2011); 95
th
 world’s most 
innovative company (Forbes “The world’s most innovative companies”, 2011); it ranked third 
in the world’s most admired Companies in Medical&Other Precision Equipment (Fortune 
“World’s Most admired companies”, 2011); and was ranked 68th best company to work for 
(Fortune “100 Best companies to work for”, 2011).   
 
Stryker’s sales have been constantly increasing for 31 years and reached 7.3 billion dollars in 
2010. The annual compound growth rate in sales is equal to 20% for the 31-year period.  
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Annual 
Growth 
Rate 
12% 17% 12% 0,07% 9% 
 
Figure 4. Stryker Net Sales 2006-2010 and Annual Growth rate  
 
Stryker became public in May 1979 when it started listing its shares on NASDAQ stock ex-
change. Since 1997 Stryker is being listed on New York Stock Exchange. In the end of 2010 
the share capital of the company was around 7 billion dollars with 396 million weighted aver-
age shares outstanding.  
 
3.2 Zimmer  
 
Zimmer is an American Public listed company included in the list of leading manufacturers of 
orthopedic implants. Zimmer is engaged in manufacturing, design, development and market-
ing of reconstructive implants, dental implants, trauma products, spinal implants and surgical 
equipment. Zimmer’s share in a global market represents 27% of a $6.4 billion knee market, 
21% of a $5.8 billion hip market, 13% of a $1.0 billion extremities market, 6% of a $3.3 bil-
lion dental market, 5% of a $4.4 billion trauma market, and 3% of a $8.7 billion spine market. 
 
Zimmer has its offices in 25 countries and sells its products in more than 100 countries. 
American market represents 56 % of Zimmer sales, while Europe represents 26% and Asia 
16%. Zimmer’s current focus is to conquer markets in emerging countries. Therefore, it has 
just recently acquired Beijing Medical Company and expects to double the size of its sales in 
Chinese market by 2015. 
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The history of Zimmer dates back to 1927 when it was founded in Warsaw, Indiana. In 2001 
Zimmer became an independent public company and is now listed on NYSE (New York 
Stock Exchange) and SIX (Swiss Exchange).  
 
Zimmer currently employs approximately 9000 people and is constantly requiring more quali-
fied specialists because of the expanding business.  
 
The chart below provides the information on Zimmer’s net sales 2006-2010 and the annual 
growth rate table provides the information on net sales growth percentage by year. 
 
 
Annual 
Growth 
Rate 
6% 12% 6% -0,6% 3% 
Figure 5. Zimmer Net Sales 2006-2010 and Annual Growth rate  
 
Zimmer’s Sales are constantly increasing; however, there has been a decrease in 2009. De-
crease in sales in 2009 is affected by several factors. First of all, by the decrease in global 
selling prices for orthopedic implants.  The prices decreased by 1% in 2009. Moreover, the 
exchange rate in 2009 was not favorable for Zimmer as the dollar became strong compared to 
foreign currency which led to a 2% decrease in sales revenue. Moreover, Zimmer experienced 
customer losses due to implementation of several compliance initiatives. Notwithstanding the 
above-mentioned issues, the demand for Zimmer’s products is constantly increasing and is 
expected to follow the trend.  
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3.4 Smith&Nephew 
 
Smith&Nephew is a UK-headquartered company. The four key areas of its operations include 
orthopedics, trauma, wound management, and endoscopy. The company started as a small 
pharmacy in Hull founded by Thomas James Smith in 1856.  
 
The company operates in more than 90 countries worldwide and has manufacturing facilities 
in England, US, Germany, Switzerland, China, and Canada. United States represents 43% of 
group revenue, Europe represents 33% of group revenue and the rest represents 24%. 
 
Smith&Nephew went public in 1936 when it started trading its shares on London Stock Ex-
change. Since 1999 the group’s shares are also traded on New York Stock Exchange in the 
form of American Depository Shares representing five ordinary shares each.  
 
The Net Sales of the Company has been increasing throughout the whole period 2006-2010 
with a slight decrease in 2009 the reason for which is mainly explained by fluctuations in the 
currency exchange rates when dollar became stronger compared to euro, sterling and Austral-
ian dollar. 
 
Annual 
Growth 
Rate 
9% 21% 13% -1% 5% 
 
Figure 6. Smith&Nephew Net Sales 2006-2010 and Annual Growth rate  
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3.5 Financial Ratio Analysis Results 
 
3.5.1 Liquidity 
 
 
Figure 7. Quick Ratio. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
As can be seen from the chart, Stryker outperforms Zimmer and Smith&Nephew and also the 
industry average since 2008. It has the highest level of liquidity among all. Even though 
Zimmer and Smith&Nephew have lower indicators of quick ratio and underperform the in-
dustry, they are still above the rule of thumb which suggests the company should have $1 of 
cash, marketable securities and accounts receivable for every $1 of current liabilities.  
 
 
 
 
 
 
2006 2007 2008 2009 2010
Stryker 1,7 2,6 2,3 2,8 3,5
Zimmer 1,42 1,52 1,23 2,19 2,43
Smith&Nephew 1,27 0,47 1,15 1,33 1,35
Industry 1,94 2,93 2,24 2,8 2,89
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3.5.2 Profitability 
 
 
Figure 8. Return on Assets. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
In terms of Return on Assets, Stryker has been able to outperform the industry and Zimmer 
with Smith&Nephew during 2007-2009, however underperformed Zimmer in 2006 and 
Smith&Nephew in 2010. Zimmer’s return on assets has been decreasing throughout the whole 
period and fell below the industry average in 2010. The possibility of increasing the ROA lies 
either in reducing the total assets or increasing the Earnings Before Interest and Taxes. The 
first is reached by selling off the assets, while the latter is reached by reducing the administra-
tive, selling, general, R&D expenses. Smith&Nephew’s return on assets has been increasing 
since 2007 and reached its peak in 2010 with 19%. The rule of thumb suggests the company 
produces at least 5% return on its assets. Stryker, Zimmer and Smith&Nephew fulfill this re-
quirement.  
 
 
2006 2007 2008 2009 2010
Stryker 18 18 20 18 16
Zimmer 20 17 15 13 11
Smith&Nephew 17 11 14 16 19
Industry 14 12 13 13 14
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Figure 9. Return on equity. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
Smith&Nephew undoubtedly outperforms Stryker, Zimmer and the Industry. It utilizes its 
equity most efficiently among all. This happens because Smith&Nephew is able to produce 
higher net income having lower shareholder’s equity compared to Zimmer and Stryker. Zim-
mer’s return on equity has been decreasing since 2008 and reached its lowest point in 2010 
with 10% which underperforms the industry average. Stryker’s return on equity has also been 
decreasing since 2008, however, it still outperformed the industry by 3% in 2010. The rule of 
thumb suggests the company should produce at least 10% return on equity. Even though the 
companies have been able to meet this requirement, Zimmer has been on the edge in 2010 
with exactly 10% return on equity.  
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Figure 10. Gross profit margin. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
The rule of thumb suggests the company should have at least 35% gross profit margin; how-
ever, orthopedic implant industry is characterized by very high gross profit margins and is 
currently the third highest in healthcare industry behind large pharmaceutical and biotech 
companies.  
 
Zimmer has the highest gross profit margin which currently was 76% in 2010. Stryker’s gross 
profit margin is lower than of its competitors and the industry. Meanwhile, Smith&Nephew’s 
gross profit margin is higher than the industry average and Stryker but lower than Zimmer. 
2006 2007 2008 2009 2010
Stryker 69 69 68 68 69
Zimmer 78 78 76 76 76
Smith&Nehphew 72 70 72 73 74
Industry 72 72 71 71 72
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Figure 11 Net profit margin. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
The profit margin graph helps to better understand the pricing of orthopedic implants. As can 
be seen from the gross profit margin, cost of implants represents a very slight proportion of 
the total price charged by the companies. The difference between the high gross profit margin 
and low profit margin shows that the biggest share of the implant’s price is not represented by 
the cost of production but by other expenses associated with keeping up the business. Even 
though the gross profit margin is considered to be very high, net income tends to be quite low 
compared to the gross profit which is explained by Research&Development and Administra-
tive, Selling and General Expenses consuming the biggest share of the cost of products. These 
expenses keep the price of orthopedic implants unreasonably high and leave no choice for the 
orthopedic surgeons because of oligopolistic nature of the market. The prices for the products 
need to be decreased as the demand is constantly increasing and can lead to government being 
unable to cover the costs incurred by the surgeries (Borzo, 2012). The cost issue is now in the 
core of the main challenges to be solved in the industry. The author believes that the compa-
nies able to reduce their expenses will win the share of orthopedic business in the future as the 
government might demand the decrease in prices because of the increasing demand for the 
surgeries covered by the government healthcare expenditure. 
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3.5.3 Leverage 
 
 
Figure 12. Debt ratio. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
As can be seen from the chart, Smith&Nephew uses more debt finance than Stryker, Zimmer 
and the industry. This results in higher return on equity where Smith&Nephew undoubtedly 
wins the competition with the highest ratio indicators. Meanwhile, Zimmer and Stryker go for 
more equity finance and less debt finance than the industry which results in lower return on 
equity figures. Therefore, additional borrowing in this industry has a positive impact on return 
on equity. However, the rule of thumb suggests the companies should not go over 70% be-
cause more debt financing results in more financial risk (Bodie, 2009, p.98). This rule has not 
been broken by any studied company. 
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3.5.4 Efficiency 
 
 
Figure 13. Total asset turnover. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
Stryker and Smith&Nephew outperform the industry in terms of total asset utilization. 
Smith&Nephew reached the top with 84 cents in sales from every dollar of assets in 2010. 
Thus, Smith&Nephew has been utilizing its assets most efficiently during the period 2009-
2010. Stryker has been the most efficient in utilizing total assets during 2006-2008. Mean-
while, Zimmer underperforms the industry and its competitors and produced 65 cents in sales 
for every dollar of total assets in 2010. 
2006 2007 2008 2009 2010
Stryker 0,88 0,82 0,88 0,74 0,67
Zimmer 0,59 0,59 0,57 0,53 0,53
Smith&Nephew 0,86 0,76 0,84 0,83 0,84
Industry 0,71 0,69 0,7 0,68 0,65
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Figure 14. Fixed asset turnover. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
Stryker invests into Property, Plant and Equipment most effectively than Zimmer, 
Smith&Nephew and the industry. Stryker’s fixed asset turnover constantly increases through-
out the examined period and reached its peak in 2010 with 8.4 dollars generated from each 
dollar of fixed assets. The rule of thumb suggests the company generates at least 5 dollars in 
sales per dollar of fixed assets. Stryker and Smith&Nephew have been able to meet this re-
quirement and also outperform the industry. However, Zimmer underperformed the industry 
and its competitors and produced 3.5 dollars in sales per dollar of fixed assets in 2010 which 
leads to a conclusion that Zimmer needs to either increase the net sales figure with its current 
state of fixed assets or decrease the property, plant and equipment by selling them. 
 
 
 
 
 
 
2006 2007 2008 2009 2010
Stryker 5,9 6,3 6,9 7 8,4
Zimmer 4,6 4,4 3,7 3,3 3,5
Smith&Nephew 4,5 4,9 5,2 5,1 5,2
Industry 5,05 5,05 5,1 4,9 4,9
0
1
2
3
4
5
6
7
8
9
Fixed Asset Turnover 
 46 
 
Table 9. Inventory turnover analysis. Stryker, Zimmer, Smith&Nephew. 2006-2010  
Inventory Turnover*Gross Profit Margin 
Year 2006 2007 2008 2009 2010 
Stryker 179 % 174 % 166 % 156 % 157 % 
Zimmer 99 % 99 % 91 % 82 % 83 % 
Smith&Nephew 95 % 96 % 90 % 83 % 82 % 
Industry 119 % 107 % 138 % 128 % 131 % 
 
In order to examine the inventory turnover, the rule of thumb suggests that if inventory turno-
ver multiplied by gross profit margin is higher than 100, then the average inventory is not too 
high. As can be seen from the table, Stryker is more efficient in utilizing its inventories and 
sells them faster than the industry and Zimmer and Smith&Nephew. Meanwhile, the level of 
Zimmer’s and Smith&Nephew’s inventories has been increasing throughout the period. 
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3.5.5 Market value 
 
 
Figure 15. Earnings per share. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
Zimmer does not pay any dividends to its shareholders. All profits are retained and reinvested 
for the expansion of the business. Therefore, the company is able to produce higher profit on 
its shares. Zimmer’s earnings per share were almost double the industry norm in 2010 which 
means that Zimmer is highly efficient in utilizing the shareholder’s money. Smith&Nephew 
follows Zimmer in earnings per share; however, it generates lower earnings per share than 
Zimmer. Stryker has the lowest EPS figure; however, it still outperforms the industry 
throughout the whole examined period.  
2006 2007 2008 2009 2010
Stryker 2,03 2,44 2,87 2,97 3,35
Zimmer 3,47 4,08 4,07 3,95 4,36
Smith&Nephew 2,26 2,6 2,78 3,28 3,68
Industry 1,91 1,76 1,98 2,15 2,46
0
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Figure 16. Price-to-earnings. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
Price-to-earnings ratio helps the investor to check whether the stock is fairly priced, over-
priced or underpriced. P/E ratio shows how much shareholders are ready to pay for one dollar 
of the company’s earnings. The rule of thumb suggests that investors should avoid P/E ratio 
of more than 20 and look for lower priced shares. The 14-18 P/E ratio range is considered as 
fair. 
 
The chart shows that the stock of Zimmer and Stryker has been overpriced during 2006-2007, 
however, since 2008 the shares of these two companies have been fairly priced.  
 
Smith&Nephew’s stock was overpriced during 2007-2008, however, prices fell after that and 
the stock became fairly priced during 2009-2010. 
 
As can be seen from the chart, the stock of Stryker and Zimmer was priced higher than the 
industry’s average stock during 2009-2010, while Smith&Nephew’s stock was priced lower 
than the industry’s average during the same period. 
2006 2007 2008 2009 2010
Stryker 27,54 31,19 14,13 17,05 16,14
Zimmer 22,82 20,15 10,82 17,71 17,99
Smith&Nephew 11,4 35,3 25,8 14,8 13,9
Industry 28,41 33,13 19,99 16,54 14,87
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The maximum profitability from investing into shares is reached when the stock is bought 
during the “underpriced period” and sold during the “overpriced period”. Thus, for example, 
it would be most profitable to buy shares of Smith&Nephew in 2006 and sell them off in 
2007. Meanwhile, lowest prices for Stryker’s and Zimmer’s stock were registered in 2008 
which would be the recommended year to buy the shares.  
 
 
Figure 17. Earnings yield. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 
The rule of thumb suggests that earnings yield from the shares should be higher than a post-
tax government bond yield (Kumar Gautam “When to sell your stocks: 5 thumb rules!” 2010). 
Investment into shares is riskier than investment into risk-free government bond; therefore, 
investor tends to look for higher yield on shares compared to the government bond. 
 
As can be seen from the graph, shares of orthopedic implant industry produce higher earnings 
yield than a 5-year US Treasury Bill. Moreover, the companies produced higher earnings 
yield than the industry average throughout the whole examined period.  
 
2006 2007 2008 2009 2010
Stryker 3,6 3,2 7,1 5,9 6,2
Zimmer 4,4 5 9,2 5,6 5,6
Smith&Nephew 7,6 4 6,8 5,2 6,6
Industry 4,2 3 4,7 5 5,7
5-year US treasury bill
yield
3 2,4 1,1 1,9 1,4
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3.6 Altman Z-score Results 
 
In order to evaluate the probability of the studied companies of going bankrupt within the next 
20 months
3
, the Altman Z-score is applied. The results of the calculation are as follows: 
Table 10. Altman Z-score results. Stryker, Zimmer, Smith&Nephew  
Company Name Z-score 
Stryker 5,97 
Smith&Nephew  5,06 
Zimmer 4,84 
 
As the interpretation suggests, if Z-score is greater than 2.99, the company is in the ‘safe 
zone’ and the probability of bankruptcy is very low. The results calculated for each company 
are higher than 2.99, therefore the probability of these companies going bankrupt within the 
next 20 months is very low. Investment into these companies is safe. 
 
3.7 Return on shares 
 
3.7.1 Return on Investment 
 
In order to evaluate the profitability of investment into stock of Zimmer, Stryker and Smith & 
Nephew, Return on Investment formula is applied. The author assumes that investor pur-
chased a single share of each company on December 29th 2005 and sold it after five years on 
31st of December 2010.  
Table 11. Return on investment. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 Zimmer Stryker Smith&Nephew 
Purchase price (30.12.2005) 68.31 44.43 46.35 
Selling price (31.12.2010) 53.68 53.7 52.55 
Five-year dividend total 0.00 1.83 3.14 
ROI -21% 25% 20% 
                                                          
3
 20 months from the calculated date at 31.12.2010. Therefore, 20 months from 31.12.2010 is 31.08.2012 
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As can be seen from the table, Stryker has the highest Return on Investment among the three 
companies; it is followed by Smith&Nephew with 20% ROI. Meanwhile, Zimmer has a nega-
tive ROI figure which means that the price of the share decreased, and, therefore, the investor 
would have lost 21% on the investment. 
 
3.7.2 Internal rate of return 
 
Internal rate of return is defined by Bodie (2009) as “the discount rate that equates the present 
value of the project’s free cash flows with the project’s initial cash outlay”. In simple words, 
Internal Rate of Return is the discount rate which sets Net Present Value equal to zero. The 
IRR of an investment is also known as the ‘yield’ on the investment; it is the compound aver-
age annual rate of return over the period of the investment. 
 
If the investor’s required rate of return is higher than IRR, NPV will be < 0 and the invest-
ment will be value-destroying. 
 
If the investor’s required rate of return is lower than IRR, NPV will be > 0 and the investment 
will be value-creating. 
 
In order to compare the internal rate of return we need to know the investor’s required rate of 
return. The investor’s required rate of return is defined by Bodie (2009) as “the minimum rate 
of return necessary to attract an investor to purchase or hold a security”. The required rate of 
return consists of two components being the risk-free rate of return and a risk premium. Risk-
free rate of return is return required for risk-free investments, such as U.S. Treasury bill. Risk 
premium is the additional return required for taking on additional risk. As one of the main 
principles of finance states, risk requires reward; therefore, investors tend to require higher 
return for riskier investments. In our case the required rate of return is equal to 9.35 % which 
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includes 4.35% 5-year US Treasury Bill rate (U.S. Department of the treasury), and 5% risk 
premium. 
Table 12. Internal rate of return. Stryker, Zimmer, Smith&Nephew. 2006-2010  
 Zimmer Stryker Smith&Nephew 
IRR 2006-2010 -13% -4% -5% 
 
Internal rate of return for these three companies is negative and lower than the required rate of 
return; therefore, the investment is value-destroying and not worthwhile. The reason for this 
negative figure is explained by the decrease in share prices during and after the financial cri-
sis. 
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4 CONCLUSION 
 
In order to answer the first research question and compare companies to each other in order to 
identify the strongest, fastest growing and most profitable player in the field, each part of fi-
nancial ratio analysis is analyzed separately. 
 
First of all, in terms of liquidity, Stryker has the highest indicator of quick ratio.  The more 
liquid the company is, the more financially strong it is. Therefore, Stryker is considered as the 
most liquid and financially strong company among three studied companies. 
 
In terms of profitability, both Stryker and Smith&Nephew have higher than the industry aver-
age return on assets and return on equity. Meanwhile, Zimmer is utilizing its assets and equity 
slightly less efficiently than the two peers and the industry; however, it has the highest gross 
profit and profit margins among all.  
 
Regarding the debt finance, Zimmer and Stryker use slightly less debt than Smith&Nephew. 
The additional use of debt finance results in higher return on equity where Smith&Nephew 
undoubtedly leads the competition. All three companies do not exceed 70% debt rate so all of 
them are in a safe position. 
 
In terms of efficiency, Stryker is considered as the most efficient among all as it has the high-
est total asset turnover, fixed asset turnover and inventory turnover figures. Therefore, Stryker 
has the maximum productivity and the minimum expenditure regarding the utilization of its 
assets and inventory. 
 
As regarding the market ratios, it is important to note that Zimmer unlike Stryker and 
Smith&Nephew does not pay any dividends to its shareholders and reinvests all the net in-
come for the generation of higher profits. This is considered by the author as the smart strate-
gy because dividends are relatively low compared to the share’s price, so it might not make a 
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difference for a shareholder to receive annual 20 cents as dividend, however, it makes a huge 
difference for a company’s business when all the dividends are pooled together and further 
reinvested. When comparing P/E ratio for the three companies, it can be concluded that they 
are approximately equally priced during 2009-2010 with slight variations. As regarding the 
earnings yield, Zimmer was able to outperform the industry and competitors during 2007-
2009; however, Stryker and Smith&Nephew outperformed Zimmer in 2010. 
 
The future of all the studied companies looks quite safe and there is no possibility of future 
bankruptcy within the next 20 months according to Altman Z-score calculation. Therefore, 
investment into shares of these companies is quite safe. 
 
In terms of return on investment, Stryker and Smith&Nephew have the highest indicators, 
while Zimmer produced -20% return on investment. Even though the internal rate of return 
figures of all three investments showed to be negative, this is explained by the financial crisis 
which affected the world in 2007. However, Stryker has been able to outperform S&P 500 
Stock Index and S&P 500 Healthcare Equipment Index during all years 2006-2010 and pro-
duce a higher shareholder return. Meanwhile, Smith&Nephew has been able to outperform 
the Medical Devices (Median) Industry in the long-run and produce higher total shareholder 
return. However, Zimmer has been slightly less profitable than investment into S&P 500 
Stock Index and S&P 500 Healthcare Equipment Index.  
 
Stryker and Smith&Nephew outperformed the indexes in terms of shareholder return during 
2006-2010 period, while Zimmer underperformed. Even though Zimmer’s shares had slightly 
lower return than that of two other companies and the indexes, it is explained by the financial 
crisis which affected the world in 2007. While Stryker and Smith&Nephew have been able to 
recover after crisis rather fast, Zimmer failed to do so and therefore underperformed. There 
are many reasons why Zimmer’s recovery from the crisis took longer. One of the main rea-
sons is suspension of distribution of defective hip implant Durom Cup which led to huge ex-
penditures on lawsuits, investigations and losses. However, based on Financial Ratio Analy-
sis, Zimmer has higher profitability with higher operating profit and profit margins. Moreo-
ver, Zimmer’s shares always produced higher earnings per share and in 2009 and 2010 Zim-
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mer had the highest price-to-earnings ratio which means that investors believe in the future of 
the company and value it higher compared to competitors and the industry. Moreover, Zim-
mer had the highest earnings yield during 2007-2009 which means that the company produced 
higher return on every dollar invested in the company. By bringing all the above-mentioned 
facts together, it is reasonable to say that investing into Zimmer is more profitable than invest-
ing into Stryker or Smith&Nephew. The author believes that Zimmer has very perspective 
future prospects. However, Stryker and Smith&Nephew are also considered as profitable in-
vestments. 
 
Moreover, the author wants to add that it seems like there is a need for decrease in operating 
expenses. Gross profit margins are very high in the industry: the third highest in healthcare 
industry behind large pharmaceutical and biotech companies. Meanwhile, the profit margins 
are relatively low. Therefore, the cost of the product represents a very slight proportion of the 
price but general, administrative, research and development expenses consume the biggest 
share of price keeping it unreasonably high. The companies able to decrease operating ex-
penses will win the market share of the business. One way it can be achieved is decreasing the 
amount of sales representatives. The work done by sales representatives needs to be done by 
hospitals, especially maintaining the stock, assuring there are enough inventories kept in the 
warehouse and moving towards decreasing the appearance of sales representatives during 
surgeries.  
 
If companies are not able to decrease expenses, it would be harder for the government to be 
able to afford paying for an increasing amount of costly orthopedic implant surgeries. There 
might be a trend of switching to something new, like 3D printed orthopedic implants which 
might become a future of orthopedic implant industry or even a better alternative of a recently 
offered by orthopedic surgeon Kevin Stone replacement of damaged parts with lab-grown 
tissue from animals and parts of human donors. If these alternatives gain popularity, invest-
ment into orthopedic implant shares of current manufacturers might become risky. 
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7 APPENDIX 
 
Financial Ratio Analysis 
Interview 
Jenny Kähtävä 
1. What are your current responsibilities at OP Pohjola?  
 
Bank Analyst at OP Pohjola Headquarters. 
 
2. What purposes is Financial Ratio Analysis used for in OP Pohjola? (Is it useful for in-
vestment evaluation?)  
 
 Credit risk analysis 
 
3. What ratios are included in the ratio analysis in OP Pohjola? Do you think there are 
some more important ratios (green) and less important ratios (red)?  
 
 Enterprise value / EBITDA 
 (Net) Total Debt / EBITDA 
 (Net) Senior Debt / EBITDA 
 Cash flow coverage 
 Interest coverage 
 Gearing 
 Equity ratio 
 Quick ratio 
 Working capital based ratios (days outstanding) 
 
4. Is there any software used for calculating the ratios? If so, how does it work? 
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 Excel based financial models 
 
5. How long does it take to prepare FRA for a certain company? 
 
 Few minutes, entire model takes half a day 
 
6. How many people are involved in preparing FRA for one company? 
 
 One 
 
7. How are the ratios interpreted? (Are they compared with the peer companies, rule of 
thumb, industry norms?) 
 All of the mentioned examples 
 
8. Is FRA performed by OP Pohjola available online or is it strictly confidential? 
 
 Strictly confidential  
 
9. Do you find any drawbacks or pitfalls in using FRA? If so, how do you think it can be 
improved? 
 
 Ratios do not give a good representation when there is significant busi-
ness fluctuation, including economic downturns (the same goes for ra-
tios calculated based on share price)  
 Do not give any insight into how good the business or industry is 
 Without forecasts, financial ratios as purely history based, static analy-
sis do not necessarily give a good representation of the future 
 
10. Would you like to give some useful tips for performing financial ratio analysis? 
 
 High leverage (>3,5x EBITDA) needs much more cash flow analysis 
than just ratio based 
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 Equity ratio and gearing are fairly trivial in other than assessing buffers 
for bank debt in terms of enterprise value 
 Emphasis should always be on understanding the company’s cash 
flows and forecasts should always be based on understanding the busi-
ness, cost structure, pricing and production, industry and competition 
 
 
